Cisplatin + Irinotecan + Bevacizumab

Indication

Chemotherapy for locally advanced unresectable and metastatic cancer

  • Cisplatin 30 mg/m2 iv over 30 min d1, 8
  • Irinotecan (CPT-11) 65 mg/m2 iv over 30 min d1, 8
  • Bevacizumab (Avastin) 15 mg/kg iv d1
  • Q3w

References

Shah MA et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201